Acta Pharmaceutica Sinica B · 2024 · 22 citations · 33 references
PharmacyOncologyPharmaceuticsDrug DeliveryGene TherapyImmunotherapyCancer ImmunotherapyCancer NanomedicineLipid-based NanoparticlesNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsGene-targeted TherapyIntratumoral AdministrationLipid Nanoparticle Delivery SystemsLipid NanoparticlesNanoparticle DeliveryNanoparticle Delivery VectorsNanoparticle-based ImmunotherapyNucleic Acid Delivery Systems
Optimum genetic delivery for modulating target genes to diseased tissue is a major obstacle for profitable gene therapy. Lipid nanoparticles (LNPs), considered a prospective vehicle for nucleic acid delivery, have demonstrated efficacy in human use during the COVID-19 pandemic. This study introduces a novel biomaterial-based platform, M1-polarized macrophage-derived cellular nanovesicle-coated LNPs (M1-C-LNPs), specifically engineered for a combined gene-immunotherapy approach against solid tumor. The dual-function system of M1-C-LNPs encapsulates Bcl2-targeting siRNA within LNPs and immune-modulating cytokines within M1 macrophage-derived cellular nanovesicles (M1-NVs), effectively facilitating apoptosis in cancer cells without impacting T and NK cells, which activate the intratumoral immune response to promote granule-mediating killing for solid tumor eradication. Enhanced retention within tumor was observed upon intratumoral administration of M1-C-LNPs, owing to the presence of adhesion molecules on M1-NVs, thereby contributing to superior tumor growth inhibition. These findings represent a promising strategy for the development of targeted and effective nanoparticle-based cancer genetic-immunotherapy, with significant implications for advancing biomaterial use in cancer therapeutics.
33
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray, Judith E. Allen, Subhra K. Biswas et al. · Immunity · 2014 · 6.2K citations · Full text